Logo image of PASG

PASSAGE BIO INC (PASG) Stock Fundamental Analysis

USA - NASDAQ:PASG - US7027122099 - Common Stock

7.54 USD
+0.37 (+5.16%)
Last: 9/22/2025, 8:55:50 PM
Fundamental Rating

2

Taking everything into account, PASG scores 2 out of 10 in our fundamental rating. PASG was compared to 538 industry peers in the Biotechnology industry. While PASG seems to be doing ok healthwise, there are quite some concerns on its profitability. PASG does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PASG had negative earnings in the past year.
PASG had a negative operating cash flow in the past year.
PASG had negative earnings in each of the past 5 years.
PASG had a negative operating cash flow in each of the past 5 years.
PASG Yearly Net Income VS EBIT VS OCF VS FCFPASG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -71.79%, PASG is doing worse than 63.57% of the companies in the same industry.
Looking at the Return On Equity, with a value of -148.61%, PASG is doing worse than 62.83% of the companies in the same industry.
Industry RankSector Rank
ROA -71.79%
ROE -148.61%
ROIC N/A
ROA(3y)-62.31%
ROA(5y)-54.67%
ROE(3y)-88.34%
ROE(5y)-72.01%
ROIC(3y)N/A
ROIC(5y)N/A
PASG Yearly ROA, ROE, ROICPASG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

PASG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PASG Yearly Profit, Operating, Gross MarginsPASG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, PASG has more shares outstanding
The number of shares outstanding for PASG has been increased compared to 5 years ago.
There is no outstanding debt for PASG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PASG Yearly Shares OutstandingPASG Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
PASG Yearly Total Debt VS Total AssetsPASG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -13.39, we must say that PASG is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -13.39, PASG is doing worse than 78.81% of the companies in the same industry.
PASG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.39
ROIC/WACCN/A
WACCN/A
PASG Yearly LT Debt VS Equity VS FCFPASG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 3.05 indicates that PASG has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.05, PASG is doing worse than 63.57% of the companies in the same industry.
PASG has a Quick Ratio of 3.05. This indicates that PASG is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.05, PASG is not doing good in the industry: 60.78% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 3.05
Quick Ratio 3.05
PASG Yearly Current Assets VS Current LiabilitesPASG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

PASG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -188.71%.
EPS 1Y (TTM)-188.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 19.86% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y11.02%
EPS Next 2Y17.95%
EPS Next 3Y20.09%
EPS Next 5Y19.86%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PASG Yearly Revenue VS EstimatesPASG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 100M 200M 300M
PASG Yearly EPS VS EstimatesPASG Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PASG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PASG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PASG Price Earnings VS Forward Price EarningsPASG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PASG Per share dataPASG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10

4.3 Compensation for Growth

PASG's earnings are expected to grow with 20.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.95%
EPS Next 3Y20.09%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PASG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PASSAGE BIO INC

NASDAQ:PASG (9/22/2025, 8:55:50 PM)

7.54

+0.37 (+5.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)11-11 2025-11-11
Inst Owners51.79%
Inst Owner Change-3.07%
Ins Owners0.21%
Ins Owner Change0%
Market Cap23.98M
Analysts85.45
Price Target65.54 (769.23%)
Short Float %2.75%
Short Ratio0.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)10.89%
Min EPS beat(2)-6.56%
Max EPS beat(2)28.35%
EPS beat(4)2
Avg EPS beat(4)-1.62%
Min EPS beat(4)-32.14%
Max EPS beat(4)28.35%
EPS beat(8)5
Avg EPS beat(8)6.31%
EPS beat(12)8
Avg EPS beat(12)6.92%
EPS beat(16)11
Avg EPS beat(16)6.57%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-50.58%
PT rev (3m)1382.7%
EPS NQ rev (1m)18.11%
EPS NQ rev (3m)-1278.75%
EPS NY rev (1m)0%
EPS NY rev (3m)-1444.73%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.63
P/tB 0.63
EV/EBITDA N/A
EPS(TTM)-18.16
EYN/A
EPS(NY)-9.56
Fwd EYN/A
FCF(TTM)-11.35
FCFYN/A
OCF(TTM)-11.34
OCFYN/A
SpS0
BVpS12.03
TBVpS12.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -71.79%
ROE -148.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-62.31%
ROA(5y)-54.67%
ROE(3y)-88.34%
ROE(5y)-72.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.05
Quick Ratio 3.05
Altman-Z -13.39
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)49.41%
Cap/Depr(5y)403.88%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-188.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.08%
EPS Next Y11.02%
EPS Next 2Y17.95%
EPS Next 3Y20.09%
EPS Next 5Y19.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.53%
EBIT Next 3Y6.96%
EBIT Next 5Y23.29%
FCF growth 1Y59.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.55%
OCF growth 3YN/A
OCF growth 5YN/A